Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1533 ARTÍCULOS , VIENDO DEL 196 AL 210

Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease

Faustino C, Rijo P, Reis CP.

Pharmacol Res. 2017 Jun;120:68-87. doi: 10.1016/j.phrs.2017.03.020. Epub 2017 Mar 27.

Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G.

Curr Alzheimer Res. 2017;14(11):1155-1163. doi: 10.2174/1567205014666170329113007.

Preclinical to phase II amyloid beta (A(β)) peptide modulators under investigation for Alzheimer's disease

Parsons CG, Rammes G.

Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832.

Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimer's Disease

Racine E, Aspler J, Forlini C, Chandler JA.

Kennedy Inst Ethics J. 2017;27(1):1-41. doi: 10.1353/ken.2017.0002.

Tau aggregates: where, when, why and what consequences?

Frosch MP.

Neuropathol Appl Neurobiol. 2017 Aug;43(5):371-372. doi: 10.1111/nan.12400.

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li Q, Yang H, Chen Y, Sun H.

Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial

Brueggen K, Kasper E, Ochmann S, Pfaff H, Webel S, Schneider W, Teipel S.

J Alzheimers Dis. 2017;57(4):1315-1324. doi: 10.3233/JAD-160771.

The Gut Microbiota and Alzheimer's Disease

Jiang C, Li G, Huang P, Liu Z, Zhao B.

J Alzheimers Dis. 2017;58(1):1-15. doi: 10.3233/JAD-161141.

Alzheimer's disease: where next for anti-amyloid therapies?

Hardy J, De Strooper B.

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials

Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, AlSafadi AM.

BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer's Disease and Hearing Loss: A Multicenter Controlled Randomized Trial

Nguyen MF, Bonnefoy M, Adrait A, Gueugnon M, Petitot C, Collet L, Roux A, Perrot X; ADPHA study group.

J Alzheimers Dis. 2017;58(1):123-137. doi: 10.3233/JAD-160793.

EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease

Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N, Valencia-Olvera AC, LaDu MJ.

J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7.

Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?

Lassen PS, Thygesen C, Larsen MR, Kempf SJ.

J Proteomics. 2017 May 24;161:11-25. doi: 10.1016/j.jprot.2017.04.003. Epub 2017 Apr 8.

Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells

Lauschke K, Frederiksen L, Hall VJ.

Stem Cells Dev. 2017 Jun 15;26(12):857-874. doi: 10.1089/scd.2017.0003. Epub 2017 May 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias